• 1 Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Lancet, 2008 Jun 28;371(9631):2192-200.
PMID: 18586174 DOI: 10.1016/S0140-6736(08)60954-X


Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.